Kymera Therapeutics to Present Three Studies at 2024 EORTC-NCI-AACR Symposium
WATERTOWN, Mass., Oct. 23, 2024 — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company at the clinical stage, is advancing a novel class of small molecule medicines through targeted protein degradation (TPD). The company announced that fresh preclinical data from its TPD platform will be showcased in three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics happening from October 23 to October 25, 2024, in Barcelona, Spain. These presentations will feature new insights on the preclinical biomarker-based strategy for KT-253, their MDM2 degrader.
Juliet Williams, PhD, the Head of Research at Kymera Therapeutics, stated that the company has developed cutting-edge knowledge and capabilities to explore the applicability of their platform. They are creating new therapeutic hypotheses to evaluate the potential of protein degradation to tackle oncogenic proteins in validated signaling pathways. Their presentations at the symposium illustrate a toolbox of integrated approaches aimed at accelerating the discovery and development of transformative degrader medicines.
The new data underscores Kymera's research efforts to pinpoint patient groups sensitive to the KT-253 degrader mechanism and identify biomarkers linked to an acute apoptotic response in tumors. Utilizing an innovative machine learning framework, a predictive signature was developed, identifying tumor types sensitive to KT-253 that align with preclinical and early clinical findings. These include acute myeloid leukemia (AML), neuroendocrine tumors, and specific subsets of solid tumors, with or without neuroendocrine features. KT-253 is currently in a Phase 1 clinical trial to assess its potential as a treatment for solid tumors and hematological malignancies.
Additionally, Kymera will present a poster that highlights the capabilities of their innovative platform, along with a case study demonstrating how targeted protein degradation can provide enhanced potency and selectivity over traditional small molecule inhibitors for CDK2, a cell cycle regulator and key protein involved in various cancers.
The presentations at the symposium include:
- Poster Number: PB283
Title: Predictive Markers of Response to the MDM2 Degrader KT-253
Presenter: Nancy Dumont, PhD, Director, In Vivo Pharmacology
- Poster Number: PB032
Title: The MDM2 degraders KTX-049 and KT-253 are highly active in wild-type TP53 (WT p53) Merkel cell carcinoma (MCC)
Presenter: Yogesh Chutake, PhD, Associate Director, Translational Medicine
- Poster Number: PB092
Title: CDK2 heterobifunctional degraders co-degrade CDK2 and Cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
Presenter: Nicholas Kwiatkowski, PhD, Associate Director, Biological Sciences
Copies of the EORTC-NCI-AACR poster presentations will be accessible in conjunction with the conference sessions within the Resource Library section of Kymera's website.
Kymera Therapeutics is a clinical-stage biotechnology company that is pioneering the use of targeted protein degradation (TPD) to develop medicines addressing critical health issues, with the potential to significantly improve patients’ lives. The company is employing TPD to tackle disease targets and pathways that are unreachable with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders as a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also advancing degrader oncology programs targeting undrugged or poorly drugged proteins to create novel ways to combat cancer. Founded in 2016, the company has been recognized as one of Boston's top workplaces for several years.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
